Condition (MeSH)
Mastocytosis, Systemic
ClinicalTrials.gov lists 97 trials for Mastocytosis, Systemic or a narrower condition beneath it. Blueprint Medicines Corporation has the most among industry and government lead sponsors, with 10.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 more sections with rows
53 of the 97 trials are tagged with Mastocytosis, Systemic itself; the rest are tagged with a narrower condition beneath it.
When did Mastocytosis, Systemic trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 3 |
| 2016 | 2 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 66 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mastocytosis, Systemic trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 1/2 | 6 |
| Phase 2 | 27 |
| Phase 2/3 | 2 |
| Phase 3 | 8 |
| Phase 4 | 2 |
| Not applicable | 10 |
| Observational | 29 |
| Expanded access | 2 |
| Unknown | 2 |
How many Mastocytosis, Systemic trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 10 |
| Active, not recruiting | 7 |
| Available | 1 |
| Completed | 53 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mastocytosis, Systemic trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Blueprint Medicines Corporation | 10 |
| Novartis Pharmaceuticals | 5 |
| Cogent Biosciences, Inc. | 3 |
| National Cancer Institute (NCI) | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Mastocytosis, Systemic? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Avapritinib | 5 |
| Midostaurin | 4 |
| Bezuclastinib | 3 |
| Imatinib | 3 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 7 |
| Total Body Irradiation | 6 |
| Cyclosporine 0.05% | 5 |
| Mofetil Mycophenolate | 5 |
| Peripheral blood stem cell transplantation | 4 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mastocytosis, Systemic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 31 | 6 |
| Thrombocytopenia | 28 | 3 |
| Pyrexia | 26 | 3 |
| Anaemia | 21 | 3 |
| Febrile neutropenia | 21 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Mastocytosis, Systemic? (44)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Avapritinib versus Placebo in Indolent Systemic Mastocytosis. | NEJM evidence | 2023 | Yes |
| Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. | Leukemia | 2022 | Yes |
| Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. | Blood advances | 2022 | Yes |
| Living with systemic mastocytosis: Balancing between vulnerability and resilience: A qualitative study. | European journal of oncology nursing : the official journal of European Oncology Nursing Society | 2022 | Yes |
| Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. | The journal of allergy and clinical immunology. In practice | 2021 | Yes |
Showing 5 of 44 publications.
Prevalence (14)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Systemic mastocytosis | Annual incidence | 1-9 / 1 000 000 | Italy | Not stated | Exact |
| Systemic mastocytosis | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Systemic mastocytosis | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Systemic mastocytosis | Annual incidence | 1-9 / 1 000 000 | Italy | Not stated | Exact |
| Systemic mastocytosis | Point prevalence | 1-5 / 10 000 | Netherlands | Not stated | Exact |
Showing 5 of 14 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Systemic mastocytosis | 2467 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Systemic mastocytosis | 2467 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.